Thank you for joining the weekly webinar! We are admitting audience members from the waiting room. Please allow a few moments for the webinar to begin.
Guest Speaker- Gwen Petersen
Q: I want to be more involved in ALS research. Where do I start?


You can sign up to receive Research Notifications through The National ALS Registry: https://www.cdc.gov/als/. ALS TDI's Clinical Trials page: https://www.als.net/als-research/als-clinical-trials/.

Sign up for global clinical trial updates from ALS TDI: info@als.net.

Q: What vitamins and supplements are you taking? What does your regimen consist of?

A: Here is a link to Dr. Bedlack's most recent ALSUntangled webinar called 'Vitamins and Supplements in ALS': https://neals.org/people-living-with-als/educational-webinars/alsuntangled-vitamins-and-supplements-in-als

Richard Bedlack on ALS Reversals: An Update for 2022 (EverythingALS webinar): https://www.youtube.com/watch?v=TKBkx3gJ41Q

Q: Do I need genetic testing? How do I get genetic testing?

A: I say yes but talk to your doctor. Prevention Genetics x Ionis: https://bit.ly/3OTB3pK. They will mail a kit to home, so there is no need to go anywhere. A doctor needs to approve the request, but it does not need to be a neurologist – it can be a PCP as well. If you enroll in ARC, ALS TDI will sequence your genome at no cost. You can meet with a genetic counselor, either in-person or via telehealth, through the National Society of Genetic Counselors (NSGC): https://www.nsgc.org/.
HEALEY ALS Platform Trial:

- **Regimen A**
- **Regimen B**
- **Regimen C**
- **Regimen D**
- **Regimen E**
- **Regimen F**
- **Regimen G**

Common Protocol and Shared Infrastructure

- **Screen for eligibility**
- **Randomization 3:1**
- **Active**
- **Placebo**

Enrollment:
- **Screening Period**
- **Randomized Period** (24 weeks)
- **Open-Label Extension Period** (Active Treatment Extension)

Enrollment Status:
- **Enrollment Complete**
- **Enrolling**

Logos and Logotypes:
- Seelos Therapeutics
- Calico
- Denali Therapeutics
Enrollment Update: Regimen F and Regimen G

- **269** Participants consented to Master Protocol since RGF and RGG initiated

- **216** Participants assigned to RGF or RGG

- **162** Participants randomized within RGF or RGG (enrollment goal ≈240 per regimen, ≈480 total)

Thank You for your partnership in ALS research (as of 8/17/23)
59 Sites Currently Active

(as of 8/17/23)

Nova Southeastern University
Essentia Health
Texas Neurology
Mass General Hospital
University of Nebraska
Hospital for Special Care
Henry Ford Hospital
Augusta University
Beth Israel Deaconess
University of Texas HSC
University of Colorado
Ohio State University
Cedars Sinai Medical Center
Duke University
Wake Forest University
Saint Alphonsus
UMass Worcester
Lehigh Valley
Thomas Jefferson
University of South Florida
University of Pennsylvania
SUNY Upstate
University of Iowa
California Pacific Med Center
Houston Methodist
Vanderbilt University
University of Minnesota
Washington University
Barrow Neurological Institute
University of Miami
Temple University
University of Virginia
Johns Hopkins University
University of Southern CA
Holy Cross Hospital
University of Washington
University of Utah
Penn State Hershey
University of Michigan
University of Kansas
Stony Brook University
University of Cincinnati
Mayo Clinic Rochester
Northwestern University
Georgetown University
Kaiser, Los Angeles
University of Pittsburgh
Virginia Commonwealth
Med College Wisconsin
University of CA, San Fran
University of Florida, Gainesville
Providence Brain and Spine
Cleveland Clinic
George Washington University
Hackensack University
Swedish Medical Center
University of Kentucky
Dartmouth Hitchcock

https://bit.ly/3g2NZr5

Site Map & Contacts:
## Checking Site Status Online

Contact a study team near you to discuss enrollment opportunities

### List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants. Sites marked "Active, Not recruiting" are active in the Platform Trial (for example, they are following participants in ongoing regimens that have already completed enrollment) but are not enrolling new participants at this time.

<table>
<thead>
<tr>
<th>Site</th>
<th>State</th>
<th>Enrollment Status</th>
<th>Trial Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrow Neurological Institute</td>
<td>AZ</td>
<td>Recruiting</td>
<td>Whitney Dailey</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>CA</td>
<td>Recruiting</td>
<td>Sophia Mostowy</td>
</tr>
<tr>
<td>Forbes Norris MDA/ALS Research Center, California</td>
<td>CA</td>
<td>Recruiting</td>
<td>Teji Dulai</td>
</tr>
<tr>
<td>Pacific Medical Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser Permanente, Los Angeles Medical Center</td>
<td>CA</td>
<td>Recruiting</td>
<td>Mary H. Berganza</td>
</tr>
</tbody>
</table>

[https://bit.ly/3g2NZr5](https://bit.ly/3g2NZr5)
Upcoming Webinars:
August 24th - weekly Q&A webinar

*August 31st webinar canceled

Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:

https://bit.ly/3r6Nd2L

ALS Link sign-up:
https://bit.ly/3o2Ds3m